Nifty 500 Multicap 50:25:25 News and Updates

Name: Latest research reports of Godrej Consumer Products Ltd. authored by Anand Rathi and published by - Trendlyne research reports.
Item: Godrej Consumer Products Ltd.
Rating: 5
Author: Anand Rathi

Keep track of all breaking news on Nifty 500 Multicap 50:25:25 from all sources in a single place.

Load latest

Godrej Consumer Products Ltd.

25 Sep 2025

1152.80

0.45%

A Fab! performance seen ahead; retaining a Buy

Buy: Godrej Consumer Products Ltd.

Anand Rathi

With the GST cut boosting soaps and men’s grooming range (~35% of its domestic range) and innovations (Godrej Fab, Godrej Ninja) scaling up well, Godrej Consumer Products is an attractive play on consumption recovery.

Anand Rathi released a Buy report for Godrej Consumer Products Ltd. with a price target of 1430.0 on 25 Sep, 2025.

Grasim Industries Ltd.

25 Sep 2025

2808.00

0.02%

Market share gain in paints a key near-term priority

Buy: Grasim Industries Ltd.

Target

Motilal Oswal

Grasim Industries (GRASIM) organized an interaction with senior management, who shared their perspectives on the Paints business and highlighted new initiatives being implemented in this segment.

Motilal Oswal increased Buy price target of Grasim Industries Ltd. to 3550.0 on 25 Sep, 2025.

Hindustan Aeronautics Ltd.

25 Sep 2025

4837.60

-0.16%

Ticking all the right boxes

Buy: Hindustan Aeronautics Ltd.

Target

Motilal Oswal

Hindustan Aeronautics (HAL) has received the follow-on order of 97 light combat aircraft (LCA) Mk1A worth INR624b from the Ministry of Defence (MoD). This is in addition to the previous order of 83 Tejas LCA Mk1A received in Jan’21.

Hindustan Aeronautics Ltd. is trading above all available SMAs

Bajaj Finance Ltd.

25 Sep 2025

1016.55

0.76%

Steady growth with strong return ratios

Buy: Bajaj Finance Ltd.

Target

Sharekhan

BAF’s AUM is expected to grow at 25% (CAGR) for FY25-FY27, driven by favorable government reforms, such as the reduction in GST on auto and consumer durables, which is expected to drive demand.

Bajaj Finance Ltd. is trading above all available SMAs

Minda Corporation Ltd.

25 Sep 2025

594.35

2.54%

Company Update:Minda Corp

Buy: Minda Corporation Ltd.

Target

Axis Direct

Given the strong growth trajectory and healthy balance sheet, the stock is valued at a 36x multiple on FY28E EPS (unchanged), arriving at a target price of Rs 690/share (vs. Rs 600 earlier), implying a 19% upside from CMP.

Deven Choksey released a Buy report for Minda Corporation Ltd. with a price target of 596.0 on 30 Sep, 2025.

Cochin Shipyard Ltd.

25 Sep 2025

1839.80

-0.71%

Cochin Shipyard

Buy: Cochin Shipyard Ltd.

Target

ICICI Direct

We expect CSL to witness healthy growth in revenues & profitability over FY25-28E, led by execution pick-up in both the segments and increasing share of margin accretive ship-repair segment. We estimate revenue & PAT...

ICICI Direct increased Buy price target of Cochin Shipyard Ltd. to 2240.0 on 25 Sep, 2025.

Whirlpool of India Ltd.

25 Sep 2025

1193.40

0.85%

FY25 annual report analysis: Revival in business earnings but other income/ PBT remains ~40%

Sell: Whirlpool of India Ltd.

Target

ICICI Securities Limited

Other income to PBT is ~40% in FY25. The valuation multiple (P/E) based on core business earnings, i.e., excluding cash and tax-adjusted other income, stands at 71x on FY25 earnings. The company gained market
shares in both washing machine and refrigerators in FY25, despite a highly competitive landscape.

Whirlpool of India Ltd. has lost -49.49% in the last 1 Year

Lupin Ltd.

24 Sep 2025

1924.80

-0.65%

Lupin gets tentative nod from USFDA for generic HIV treatment drug

Business Standard

Pharma major Lupin Ltd on Wednesday said it has received tentative approval from the US health regulator for its generic version of Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets used to treat human immunodeficiency virus (HIV) infection. The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets of strength 50 mg/200 mg/25 mg, Lupin said in a regulatory filing. This product would be manufactured at Lupin's Nagpur facility, it added. Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets, 50 mg/200 mg/25 mg are bioequivalent to Biktarvy Tablets, 50 mg/200 mg/25 mg of Gilead Sciences, Inc., and indicated for the treatment of human immunodeficiency virus infection in adults and pediatric patients weighing at least 25 kg, it added. Citing IQVIA MAT July 2025 data, Lupin said the Bictegravir, Emtricitabine, and Tenofovir Alafenamide tablets (Biktarvy) had

Number of FII/FPI investors increased from 979 to 987 in Jun 2025 qtr.

Polycab India Ltd.

24 Sep 2025

7595.50

-0.26%

Polycab India block deal: Promoters likely to sell 0.8% stake worth Rs 887 crore on Thursday: Report

Economic Times

Promoters of Polycab India are expected to sell up to 0.81% stake through block deals, setting a floor price of Rs 7,300 per share to potentially raise Rs 887.6 crore. Several promoters, including Inder T. Jaisinghani, will participate in the sale, following a recent dip in Polycab's share price after hitting a 52-week high.

Polycab India Ltd. has gained 50.68% in the last 6 Months

Polycab Promoters To Sell 1.2 Million Shares Via Block Deal Worth Rs 880 Crore

NDTV Profit | 24 Sep 2025

ITC Ltd.

24 Sep 2025

399.80

-0.24%

Hospitality body seeks 5% GST with 50% ITC on hotel rooms under 7,500

Business Standard

HRAWI urges GST reforms proposing 5 per cent GST with 50 per cent ITC or 18 per cent GST with full ITC on hotel rooms under 7,500 to balance growth and consumer benefits

ITC Ltd. is trading below all available SMAs

Nifty 500 Multicap 50:25:25 PB	3.7
Nifty 500 Multicap 50:25:25 PE	26.1
Nifty 500 Multicap 50:25:25 DIV	1.0
Nifty 500 Multicap 50:25:25 EPS	619.5